Principal Securities Inc. Acquires 1,066 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Principal Securities Inc. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 881.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,187 shares of the biopharmaceutical company’s stock after purchasing an additional 1,066 shares during the quarter. Principal Securities Inc.’s holdings in Alnylam Pharmaceuticals were worth $279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Huntington National Bank grew its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth $29,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the 4th quarter worth $33,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $42,000. Finally, True Wealth Design LLC boosted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,356 shares of company stock worth $22,498,551 in the last 90 days. 1.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Scotiabank cut their target price on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research report on Friday, February 14th. Finally, Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $299.48.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $250.59 on Monday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a fifty day moving average price of $254.14 and a 200 day moving average price of $263.05. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a market cap of $32.44 billion, a PE ratio of -115.48 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.